Quidel Corp (NASDAQ: QDEL) reported Q2 EPS of $1.86, $0.77 better than the analyst estimate of $1.09. Revenue for the quarter came in at $201.8 million versus the consensus estimate of $189.79 million.

“Our strong second quarter results were driven by significant demand for COVID-19 diagnostic products, and reflected our organization's ability to quickly develop and scale diagnostic products that are making a difference in people's lives,” said Douglas Bryant, president and chief executive officer of Quidel Corporation. “In the quarter, we also made excellent progress on our product pipeline and on our sourcing and manufacturing capacity initiatives. As a point-of-care diagnostics leader, we are proud to expand access to affordable testing, and provide answers to some of the most vulnerable.”

For earnings history and earnings-related data on Quidel Corp (QDEL) click here.